[ PMID: 5947307] TO THE EDITOR: I am responding to Gepner and colleagues' article on the effects of moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes (1). The alcohol industry has transformed consumption of an addictive carcinogen into an enslaved lifestyle choice with massive marketing and advertising ($3.5 billion in 2011 according to the Federal Trade Commission [www.adweek.com/news/advertising -branding/ftc-study-revealshow-alcohol-advertisers-use -digital-marketing-156430]). To promote it as healthy seems unnecessary!
The editors have overplayed scientific findings about incomplete and complex facts in their patient summary about the CASCADE (Cardiovascular Diabetes and Ethanol) trial: "This long-term trial showed that a healthy diet and moderate [they did not provide a specific amount] alcohol intake, particularly red wine, were associated with better lipid and glucose control than water and had no significant harmful effects" (2) . This statement is even more surprising because Gepner and colleagues clearly underlined limitations: a very specific population (well-controlled diabetics, alcohol abstainers, and nonsmokers), an unblinded study without a placebo (for example, no grape juice), and surrogate end points (1) . They also cautiously concluded that initiating wine intake "modestly decreases cardiometabolic risk" and was "apparently safe" (emphasis added). In summary, despite 2 years of follow-up, which must be commended, this trial remains a kind of phase II study.
The "French paradox," from studies sponsored and publicized by the alcohol lobby, is not observed when selection bias is avoided (3) , and moderate alcohol consumption is not associated with reduced all-cause mortality (4) . Moreover, alcohol consumption causes a dose-related increase in the prevalence of oral cavity, pharynx, esophagus, and breast cancer beginning with 1 to 2 drinks daily (the dose in the CASCADE trial) (3) . Considering the 2-fold increase in cancer risk in persons with type 2 diabetes, this issue is major.
The effect on public health cannot be ignored. The one third of Health eHeart participants who believed alcohol to be heart healthy drank substantially more than the other participants and cited the lay press as the origin of that perception (5) . Hits from "diabetes wine" on Google News provide alarming results, and the consequence of "sciensationalism" (sensationalism in science) cannot be ignored.
The American Heart Association states, "If you drink alcohol, do so in moderation. Drinking more alcohol increases such dangers as alcoholism, high blood pressure, obesity, stroke, breast cancer, suicide and accidents," and the American College of Cardiology wisely comments, "as Saint Augustine put it . . . complete abstinence is easier than perfect moderation" (www.acc.org/latest-in-cardiology/articles/2015 /01/05/13/06/alcohol-consumption-and-cvd-the-case-for -moderation?w_nav=LC).
Finally, could Gepner and colleagues provide data about the socioeconomic characteristics of their population and estimate the proportion of participants recruited among their cohort of patients with type 2 diabetes? 
Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies

TO THE EDITOR:
The recent article by Sanghavi and colleagues reports interesting Medicare claims data on the reduced survival of patients receiving advanced life support (ALS) versus basic life support (BLS) ambulances (1) . Unsurprisingly, as with all research, this study raises important questions about bias and confounding.
First, the authors used a cross-sectional design with no estimate of pre-post change and no adequate counterfactual (control). Although conducting a randomized, control trial (RCT) is difficult, a hierarchy of quasi-experimental (non-RCT) designs produce differing levels of validity of causal inferences (2). The cross-sectional design, with or without propensity score adjustments or instrumental variables (IVs), is not included as evidence in international systematic reviews (3). Although natural experiments of changing ambulance services are hard to find, this weak design casts doubt on the authors' near-causal inferences that "we found similar or better health outcomes associated with prehospital BLS than ALS." Second, although the authors attempt to simulate randomization through IVs, one of the authors, Dr. Zaslavsky, coauthored our 2014 Annals study that found 20 years of similar regional IVs in comparative effectiveness research were probably confounded by unmeasured variables (4). County-level variation in ALS versus BLS is unlikely to be random.
Third, Table 1 in the article provides almost no clinical description of patients served by ALS and BLS. To be more useful, it should have included direct comparisons of the severity of the 4 conditions prompting the call. Is near-fatal trauma more likely to receive ALS? Many programs triage ALS, falsely associating it with excess death rates. The authors' year-old comorbidity measure has limited relevance to the high-acuity survival outcome. In addition, ALS patients travel farther for all 4 study conditions, live in less metropolitan settings, have fewer options for trauma centers and teaching hospitals, and are younger. This suggests the presence of other differences that were not measured.
Given controversies regarding the value of ALS and its importance for health policy, more rigorous controlled studies are warranted. This study is a useful contribution but also illustrates the difficulty of studying the highly varied and complex health systems in the United States. We must apply the strongest research design whenever possible. First, the authors used propensity score-weighting methods. According to a previous study the authors cited (2), if the propensity score for individual i is π i (that is, the probability to receive ALS in this case), the weighting strategy is the inverse of π i for ALS and the inverse of 1 Ϫ π i for BLS. This method is well-known as inverse probability of weighting. However, the authors' weighting method strategy mentioned in their supplementary material was 1 Ϫ π i for ALS and π i for BLS. We wonder whether this was appropriate.
Stephen
Second, the authors used a unique instrumental variable method for main results. They first estimated a county-level probability of ALS use from a nonlinear regression model and then used this predicted probability as instruments in the first stage of 2-stage least-squares (2SLS) methods. We want to know the result when using typical 2SLS methods. Conventional 2SLS tends to be biased when the instrument is very weak (3 IN RESPONSE: Although we agree with Dr. Soumerai that randomized trials of prehospital care would be useful, they are unlikely to be done. In their absence, the best available observational study designs must be used. We disagree with Dr. Soumerai's characterization of all IV designs as weak. Just as applications of the difference-in-differences designs that Dr. Soumerai favors may vary in strength, so too do IV applications.
The key untestable assumptions for valid IV analyses are that the instrument affects the dependent variable only through the variable being instrumented for and is uncorrelated with omitted predictors of the outcome (1, 2). These assumptions are probably satisfied in our study. Although the variation across counties in the proportion of ALS ambulances is not randomized, it does appear to be idiosyncratic, driven in part by local political decisions. Thus, our IV analysis approximates a randomized trial with multiple groups that vary the proportion of ALS ambulances. One must assume that neither the severity (within diagnosis) of emergent conditions across counties (within states) leading to ambulance transport nor the quality of hospital care is associated with ALS penetration. The former assumption is plausible but untestable for 4 of the diagnoses; we control for severity in the case of trauma. The latter assumption is testable and is not rejected.
Dr. Soumerai cites an article critical of IVs commonly used in comparative effectiveness research, for which he and Dr. Zaslavsky were coauthors (3). That article noted that the effects of regional variation in an instrument might be mediated through regional correlates, such as income or urbanicity, violating IV assumptions. Our analysis controlled for these and several other regional characteristics. It also included a falsification test that showed acute inpatient mortality not after emergency transport did not exhibit the same regional patterns as postambulance mortality. That article concluded, "The assumption that the instrument is only related to the out-come through the treatment may apply best to specific, focused, plausibly exogenous interventions or events, such as natural experiments . . . or changes in policy or technology." We consider it probable that after the controls in our modeling strategy, our instrument fits this description.
We appreciate Dr. Tsutsumi and colleagues' attention to technical detail. Inverse probability (Horvitz-Thompson) propensity score weighting is only one of many weighting schemes that simulate covariate balance for causal comparisons, but it does not minimize variance or even always have a finite expected value (4). Our (1 Ϫ π i , π i ) weighting yields exact mean balance when used with propensity scores from logistic regression and minimizes variance over all balancing weights (4). It estimates an average treatment effect weighted to a population distribution constituting the overlap of distributions in treated and control groups, nearest to equipoise between treatments.
Our Appendix A8 reports first-stage F statistics exceeding 1000 in each diagnosis group, implying our instrument is strong, and eTable 5 shows the variation in the predicted probability of ALS for each diagnosis. 
Is Prehospital Advanced Life Support Harmful?
TO THE EDITOR: We read Sasson and Haukoos' editorial (1) with interest. In an ideal world, prehospital care would be consistent with evidence from randomized clinical trials that assess the efficacy of each potentially available treatment method for each patient subgroup. Large-scale observational studies like ours (2) would then assess the effectiveness of these treatments as applied in the field, like similar studies of treatment alternatives in other, better-researched fields of medicine. Because no such evidence base exists for prehospital emergency care, our observational findings assume greater importance. Despite their limitations, they provide powerful evidence that the "package" of practices and services associated with advanced life support (ALS) is associated with worse outcomes than that of basic life support (BLS) in several of the most common and serious conditions that require emergency transportation for elderly patients.
In a randomized clinical trial, outcomes can be compared without knowing details of the clinical procedures in each group, the patients' intermediate health status, or the specific biological mechanisms involved. To compare average outcomes of patients treated by ALS or BLS providers, it is similarly not necessary to know the details of the interventions, the patients' intermediate health status, or the mechanisms causing differences in outcomes. In fact, adjusting for variables influenced by the ambulance type, such as specific clinical interventions or scene and transport times, is inappropriate for estimating a treatment effect.
Our results establish that the bundle of services associated with ALS on average leads to worse outcomes than that associated with BLS, with 1 contrary case highlighted by Sasson and Haukoos (acute myocardial infarction, determined by propensity score analysis). The important next step is to identify which elements of the ALS bundle of services, if any, are beneficial for which patients and under which circumstances and, conversely, which are most harmful-that is, which would produce the negative average effects that we estimated for most diagnoses and end points.
Sasson and Haukoos' assertion that ALS may not be better than BLS but cannot be worse is at odds with our findings. The Canadian OPALS (Ontario Prehospital Advanced Life Support) study that they cite to support equivalence between ALS and BLS found worse outcomes with ALS for trauma patients with low Glasgow Coma Scale scores. Moreover, extrapolating findings from a carefully monitored, controlled trial in Canada to the average, unmonitored emergency medical service in the United States is problematic.
Despite our differences, we agree with Sasson and Haukoos that the evidence base for prehospital care is sorely lacking. It is crucial that our system for this care be consistent with scientific evidence.
Prachi Sanghavi, PhD
The University of Chicago Chicago, Illinois
IN RESPONSE:
We believe that Sanghavi and colleagues' study (1) adds nicely to the discussion about the effectiveness of emergency medical services systems in the United States and highlights potentially important areas where further scientific work is needed. However, we are not convinced that their results are definitive or conclusive. Results from observational data, including large, administrative data sets, may supplement practice and policy, but by their very nature tend to be limited (2, 3). We believe that more specified prospective research, including use of quasi-experimental, cluster randomized, and pragmatic methods, must serve as the scientific framework for understanding the effectiveness of prehospital practice.
The OPALS study (4) is also more complex than Sanghavi and colleagues imply. They claim that this study's results, which showed worse outcomes among major trauma patients with initial Glasgow Coma Scale scores less than 9, support their findings. However, they ignore the mortality equivalence between BLS with defibrillation capabilities and ALS for patients with out-of-hospital cardiac arrest (5.0% vs. 5.1%, respectively) (5) and the survival advantage of ALS over BLS among patients with respiratory distress (14.3% vs. 12.4%, respectively) (6) .
The findings from the OPALS study point generally to the importance of context and specifically to the need to understand the effect of individual prehospital interventions. Sanghavi and colleagues' study points to the former but does not, and cannot, address the latter. The OPALS studies, as a whole, are the largest prospective prehospital trials to assess systemwide care performed to date and strongly support heterogeneity in effectiveness among prehospital interventions.
We suspect that the truth in terms of effective emergency medical services care lies somewhere in the middle, is more nuanced than Sanghavi and colleagues suggest, and depends on the population and disease process. Contrary to their suggestion, emergency medical services systems are monitored in the United States; however, this oversight must be rooted in a deeper scientific emphasis across multiple levels, including the intervention, population, emergency medical technician or paramedic, and system in which they operate. This point is usually ignored in the intense science of providing medical care. Relying on patient satisfaction scores from surveys is not the answer to this malady. As it stands now, the cure is worse than the disease.
Physicians' main objections to using patient satisfaction scores are not the themes mentioned in this article. Patient satisfaction does not correlate with quality of care in any randomized, controlled trials. If we insist on randomized trials and evidence-based data for every intervention or procedure in medicine, our approach to this area should be no different. There is no reason to compromise on the gold standard when we deal with a vital topic. The quality of evidence supporting adoption of patient satisfaction to various purposes is poor. An article on patients undergoing elective cranial neurosurgery reported that overall patient satisfaction may merely reflect patient experience and subjective postoperative health status and therefore is a poor proxy for quality of care in this setting (2).
The objections to adopting patient satisfaction scores to pay physicians are not related to the details of or time wasted during the process or the diversion of scarce resources or because patients are not qualified judges of physician performance. Practicing physicians object to the way that these scores are developed and adopted without any scientific basis. Hospitals get no credit for a satisfaction score of 4 out of 5. Adopting this methodology into physician payment formulas is unscientific. How did we determine that "good" is not good enough and only "very good" should count?
Nash currently has a rating of 4 out of 5 stars on a Web site (3). Even if we concede that these online surveys may not be accurate because of several reasons, 5 other physicians listed on the same page practicing within a 0.25-mile range scored 5 out of 5 stars. Does this mean that Nash performs 20% below his peers and is not eligible for a single valuebased point as it stands now?
The patient satisfaction story parallels the board certification story. The American Board of Internal Medicine has gotten carried away by certification requirements. Furthermore, ever more unattainable standards were added to measure physician competence, prompted by experts who have nothing to do with practicing medicine and are unaware of the pressures and realities of current practice environs. In the end, physicians revolted en masse and the American Board of Internal Medicine had to backpedal. Nonphysician experts were devising complicated programs without any scientific merit to measure the competency of physicians.
Patient satisfaction and value-based purchasing are big business. No one can understand or follow the program details. Hospitals have to employ legions of personnel to tease out the details of the latter to recoup some of the money subjected to penalties.
We have to acknowledge, measure, and improve patient experience. Rather than blindly applying current patient satisfaction scores to payment methods, we have to refine them before prime time. Maybe we have to include practitioner satisfaction in the measure. Are physicians happy practicing in the current settings? How satisfied are they that the requirements of practice cause barriers that affect the quality of care they provide? About the time they get to spend with the patient? About the adherence of their patient population? Maybe we need a composite score that includes patient and physician satisfaction.
Finally, Nash received Press Ganey's inaugural Physician of the Year Award (4), which is a clear conflict of interest that the article does not acknowledge. IN RESPONSE: I am pleased that Dr. Kumar agrees that the experience of patients and families is important. That was the central thesis of my article. We also agree that there is no convincing evidence that patient satisfaction is a "proxy" for quality of care. I did not assert that it is. In fact, I believe that patient experience and quality must both be measured precisely because each is important and they are distinct from one another.
P. Dileep Kumar, MD
Dr. Kumar objects to using patient experience scores to modify payments to hospitals and physicians. I did not advocate for using scores this way. I did stateaccurately-that the Centers for Medicare & Medicaid Services has adopted payment models that incorporate these scores. I agree that there are methodological challenges in doing so. My article is not an endorsement of the Centers for Medicare & Medicaid Services or other "pay-for-performance" programs. Although space limitations precluded my discussing it, I have advocated for, and led an institutional effort to implement, the public reporting of physician-specific scores-not tying them to compensation.
Dr. Kumar also took a couple of personal shots about my own patient experience scores and an alleged conflict of interest. He cited my patient satisfaction score of 4 out of 5 stars based on a handful of surveys on a Web site that invites comments from anyone (patients or not) and offered that as evidence of the absurdity of value-based compensation models. Once again, I did not advocate for payment tied to ratings and certainly not to ratings based on this kind of methodology. And, for the record, on the basis of our medical group's public reporting initiative, my own patient experience score (derived from a validated survey tool and a sufficient sample size) averages 4.9 out of 5.0 (www.northshorelij.com /find-care/find-a-doctor/cardiovascular-disease/dr-ira-s-nash -md-11360536#/patient-ratings).
Finally, I am proud to say that Dr. Kumar is correct in reporting that I received Press Ganey's inaugural Physician of the Year Award. I was recognized, in part, because of the transparency initiative of the North Shore-LIJ Medical Group (now Northwell Health Physician Partners), which I lead, and in part because of my advocacy for patient experience. This advocacy is evident in my blog (www.nslijmdblog.com) and my article in Annals, which was written, accepted, and published well in advance of my receiving this award. 
Ira S. Nash, MD
Accuracy of Peripheral Thermometers for Estimating Temperature
TO THE EDITOR:
We read with great interest Niven and colleagues' review (1) about the accuracy of peripheral thermometers for estimating core body temperature. The authors found that both of the 95% limits of agreement between peripheral and central thermometers were outside the predefined clinically acceptable range (±0.5°C) and that the most commonly used peripheral thermometers have poor diagnostic accuracy for fever and hypothermia. They concluded that peripheral thermometers do not have clinically acceptable accuracy.
Although the question is interesting, we wonder whether their findings should change clinical practice. Indeed, before we recommend the routine use of central thermometers to estimate body temperature, evidence showing that a difference in temperature of at most 1.4°C is clinically significant is warranted. It should be proved that a precise temperature assessment is able to improve clinical outcomes. If obtaining the most accurate evaluation of body temperature would not change clinical practice, the use of an invasive method to assess it could be inappropriate. Along the same line of reasoning, because noninvasive evaluation of blood pressure has been proved to be less accurate than invasive evaluation (2), one might say that an arterial line should be placed to measure blood pressure.
Finally, the studies included in the meta-analysis are heterogeneous in patient selection (they included adult and pediatric patients in the intensive care unit, emergency department, and surgical and medical wards), design, index tests, and reference standards considered. This factor might affect the accuracy of the results, leading to questionable clinical application (3). IN RESPONSE: Dr. Bonzi and colleagues raise 2 questions about our meta-analysis examining the accuracy of peripheral thermometers. A fundamentally important concern is the effect of interstudy heterogeneity on the clinical applicability of our pooled analyses. Although this heterogeneity was the main limitation of our meta-analysis, we believe that our pooled analyses remain clinically applicable.
First, data were pooled across all studies, because our main objective was to describe peripheral thermometer accuracy. Second, we recognize that clinicians caring for different populations of patients benefit from data specific to a population or thermometer; therefore, we conducted prespecified subgroup analyses to examine the effects of many factors on thermometer accuracy. These analyses showed that peripheral thermometer accuracy mostly depended on thermometer factors, with the most accurate ones being properly calibrated electronic oral and tympanic membrane devices and the least accurate being axillary thermometers. Third, interstudy heterogeneity is a common finding in meta-analyses of diagnostic tests in contrast to meta-analyses of randomized trials of therapeutic interventions and does not invalidate the pooled data (1).
Dr. Bonzi and colleagues also question the importance of accurate temperature measurement in the context of outcomes of patient care. Few diagnostic tools have been shown to be associated with important clinical outcomes (for example, death), and, to the best of our knowledge, no studies have examined the association between temperature measurement accuracy and clinical outcomes. However, we believe that accurate measurement may be important in guiding the care of certain patient populations.
First, strong data link fever, hypothermia, or both to increased morbidity and mortality in surgical patients (2), critically ill patients (3), and those with brain injury (4). Moreover, among surgical patients, maintenance of perioperative normothermia reduces surgical wound infections and shortens hospital length of stay (2); thus, failure to detect hypothermia could expose these patients to potentially preventable adverse events. Although optimal temperature management strategies for critically ill patients and those with brain injury remain unclear, accumulating further clinical and research experience in these populations depends on accurate temperature data. Second, among immunosuppressed patients (for example, those with neutropenia), fever is a common sign of severe infection and inaccurate temperature data may delay diagnosis and management of potentially life-threatening conditions. As such, we believe that, until data show that accurate temperature measurements are not associated with clinical outcomes, clinicians should attempt to monitor temperature using a thermometer that balances accuracy with safety and practicality.
Daniel J. Niven, MD, MSc, PhD
University of Calgary Calgary, Alberta, Canada Content, Consistency, and Quality of Black Box Warnings TO THE EDITOR: Elraiyah and colleagues (1) propose that adding an evidence profile would improve the usefulness of black box warnings (BBWs). Although knowing the quality of evidence supporting each warning may help prescribers gauge the strength of association between a drug and an adverse reaction, we suggest that assessing the patient's risk factors for the reaction is critical to determine the warning's applicability to an individual patient. As the authors reported, all of the BBWs that they evaluated describe the at-risk population.
We have reviewed BBWs for more than 3000 prescription drugs and have noted that the content, level of detail, and number and type of adverse reactions vary widely. Some warnings, such as those about cardiovascular events and estrogen replacement therapy, are based on results from large prospective studies. Others are based on case reports or animal data (for example, those about progressive multifocal leukoencephalopathy and rituximab or teratogenicity and valganciclovir, respectively). Despite varying levels of evidence, all have strong recommendations for preventing, mitigating, or managing serious adverse reactions. Even when the evidence is of low to moderate quality (as for abacavir-induced hypersensitivity and the HLA-B*5701 allele), a patient risk assessment is standard practice (2) .
We agree with Elraiyah and colleagues that an implementation plan is important for facilitating safe use of drugs with BBWs. We have found that the drug label often provides detailed discussions and recommendations for addressing adverse reactions, although the information may be in several sections of the label and not necessarily contained in the BBW itself (3). The authors' findings that 96% of the warnings reviewed provided BBW-specific practice recommendations are consistent with our observations.
With the increased use of electronic health information systems, we believe that integrating BBW-specific information into the electronic clinical workflow could improve the usefulness of these warnings. This information should identify the drug, its associated adverse reactions, and actions to be taken. These actions should be stratified by the steps of the medication use process, including pretreatment assessments (for example, evaluation of patient risk factors) and considerations for prescribing, dispensing, administration, monitoring, or patient counseling for the drug. Clinicians could then choose to view only action items relevant to their role in the care of the patient. Rigorously maintained data on BBWs could help provide point-of-care guidance for the safe use of drugs with these warnings. Background: Clinicians usually can identify the cause of unilateral lower extremity swelling, but even experienced clinicians can be misled by rare causes of this condition.
Objective: To describe unilateral lower extremity swelling that can be mistaken for deep venous thrombosis.
Case Report: A 31-year-old woman presented to the emergency department with a 4-day history of painless, progressive right lower extremity swelling and paresthesia. Her medical history was significant for a first-trimester miscarriage and for pulmonary embolism during another pregnancy. She was hemodynamically stable. Her examination was remarkable for tense edema of the entire right leg, accompanied by erythema, calor, and distention of superficial veins, with no evidence of neurologic or vascular compromise. Lowmolecular-weight heparin therapy for suspected deep venous thrombosis was administered, and she was discharged home with arrangements for urgent Doppler ultrasonography as an outpatient.
Doppler ultrasonography of the right lower extremity demonstrated moderate compression of the right common femoral vein due to a circumferential, hypoechoic, avascular lesion ( Figure) . The patient was admitted to the hospital for further assessment and management. Computed tomography of the pelvis demonstrated a 2.0 × 1.6 -cm, fluid-filled structure with almost complete occlusion of the right common femoral vein and associated enlargement of the superficial femoral and greater saphenous veins. Aspiration yielded a viscous, serous, mucinous fluid. She was diagnosed with adventitial cystic disease of the common femoral vein and had surgical resection of the cyst. Pathology tests confirmed a benign, adventitial cystic mass with no epithelial lining of the cyst wall. She tolerated the surgery, and her symptoms resolved.
Discussion: Adventitial cystic disease is a rare disorder that can affect arteries and veins. Arterial disease often presents with claudication, and venous disease manifests as unilateral, painless swelling of the affected limb (1) . Disease of the venous system was first described in 1973, and fewer than 40 cases have been reported since (2) . Most cases involve the lower limb, particularly the common femoral vein (2) . Adventitial cystic disease is commonly mistaken for deep venous thrombosis; however, its symptoms do not resolve with anticoagulation (2-4). The disease results from a mucinous cyst formed in the vein adventitia that pathologically and structur- 
